# US 2024/0309370 A1 · Metabolic disorder-associated target gene irna compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0309370 A1
- Document ID: US20240309370A1
- Status: Published application
- Kind: A1
- Application number: 18/403,912
- Filed: 2024-01-04
- Published: 2024-09-19
- Earliest claimed: 2021-07-21
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Aimee M. Deaton; Jeffrey Zuber
- Web page: https://patentgrep.com/patent/US20240309370A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Y 301/04017: 3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3125: Methylphosphonates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a metabolic disorder-associated target gene, e.g., inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), or inhibin subunit beta C (INHBC) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a metabolic disorder-associated target gene and to methods of preventing and treating a metabolic disorder, e.g., metabolic syndrome.

## Claims

### Claim 1

A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a metabolic disorder-associated target gene selected from the group consisting of inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), and inhibin subunit beta C (INHBC) in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
a) wherein the metabolic disorder-associated target gene is INHBE and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense strand nucleotide sequences selected from the group consisting of
SEQ ID NO: 6245
5′-AAAGACGGCAGAAUGGAAAGAGG-3′ of;
SEQ ID NO: 64
5′-AAGAAAGUAUAAAUGCUUGUCUC-3′ of;
SEQ ID NO: 63
5′-ACAGACAAGAAAGUGCCCAUUUG-3′ of;
SEQ ID NO: 58
5′-AGUUAUTCUGGGACGACUGGUCU-3′ of;
and
SEQ ID NO: 6403
5′-AAAGCCAGAGUCUCAGACAAGAA-3′ of.
and
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification
b) wherein the metabolic disorder-associated target gene is INHBE and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from the complement of any one of the nucleotide sequence of nucleotides 400-422, 1430-1452, 1863-1885, 410-432, 518-540, 519-541, 640-662, or 1864-1886 of SEQ ID NO: 1;
c) wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, or 55, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the corresponding portion of the nucleotide sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, or 56;
d) wherein the antisense strand comprises a region of complementarity to an mRNA encoding the target gene, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-17, 19 and 20.

### Claim at position 2

-22. (canceled)

### Claim 23 (depends on 1)

The dsRNA agent of claim 1, wherein at least one of the nucleotides of the dsRNA agent comprises a nucleotide modification.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The dsRNA agent of claim 1, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification.

### Claim 26 (depends on 23)

The dsRNA agent of claim 23, wherein at least one of the nucleotide modifications is selected from the group consisting of a deoxy-nucleotide modification, a 3′-terminal deoxythimidine (dT) nucleotide modification, a 2′-O-methyl nucleotide modification, a 2′-fluoro nucleotide modification, a 2′-deoxy-nucleotide modification, a locked nucleotide modification, an unlocked nucleotide modification, a conformationally restricted nucleotide modification, a constrained ethyl nucleotide modification, an abasic nucleotide modification, a 2′-amino-nucleotide modification, a 2′-O-allyl-nucleotide modification, 2′-C-alkyl-nucleotide modification, 2′-hydroxly-nucleotide modification, a 2′-methoxyethyl nucleotide modification, a 2′-O-alkyl-nucleotide modification, a morpholino nucleotide modification, a phosphoramidate modification, a non-natural base comprising nucleotide modification, a tetrahydropyran nucleotide modification, a 1,5-anhydrohexitol nucleotide modification, a cyclohexenyl nucleotide modification, a nucleotide comprising a phosphorothioate group modification, a nucleotide comprising a methylphosphonate group modification, a nucleotide comprising a 5′-phosphate modification, a nucleotide comprising a 5′-phosphate mimic modification, a thermally destabilizing nucleotide modification, a glycol nucleotide (GNA) modification, a nucleotide comprising a 2′ phosphate modification, and a 2-O—(N-methylacetamide) nucleotide modification; and combinations thereof.

### Claim at position 7

-30. (canceled)

### Claim 31 (depends on 1)

The dsRNA agent of claim 1, further comprising a phosphate or phosphate mimic at the 5′-end of the antisense strand.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The dsRNA agent of claim 1, wherein the 3′ end of the sense strand is protected via an end cap which is a cyclic group having an amine, said cyclic group being selected from the group consisting of pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, and decalinyl.

### Claim 34 (depends on 1)

The dsRNA agent of claim 1, wherein the double stranded region is 19-30 nucleotide pairs in length.

### Claim at position 12

-38. (canceled)

### Claim 39 (depends on 1)

The dsRNA agent of claim 1, wherein each strand is independently no more than 30 nucleotides in length.

### Claim at position 14

-43. (canceled)

### Claim 44 (depends on 1)

The dsRNA agent of claim 1, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide; or at least one strand comprises a 3′ overhang of at least 2 nucleotides.

### Claim 45

(canceled)

### Claim 46 (depends on 1)

The dsRNA agent of claim 1, wherein one or more C22 hydrocarbon chains is conjugated to one or more internal positions on at least one strand.

### Claim at position 18

-69. (canceled)

### Claim 70 (depends on 1)

The dsRNA agent of claim 1, further comprising a targeting ligand that targets a receptor which mediates delivery to adipose tissue.

### Claim 71

(canceled)

### Claim 72 (depends on 1)

The dsRNA agent of claim 1, further comprising a targeting ligand that targets a liver tissue.

### Claim 73 (depends on 72)

The dsRNA agent of claim 72, wherein the targeting ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

### Claim 74 (depends on 72)

The dsRNA agent of claim 72, wherein the targeting ligand is an N-acetylgalactosamine (GalNAc) derivative.

### Claim 75 (depends on 72)

The dsRNA agent of claim 72, wherein the targeting ligand is one or more GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.

### Claim 76 (depends on 72)

The dsRNA agent of claim 72, wherein the targeting ligand is

### Claim 77 (depends on 76)

The dsRNA agent of claim 76, wherein the dsRNA agent is conjugated to the targeting ligand as shown in the following schematic
and, wherein X is O or S.

### Claim 78 (depends on 77)

The dsRNA agent of claim 77, wherein the X is O.

### Claim 79

(canceled)

### Claim 80 (depends on 1)

The dsRNA agent of claim 1, wherein the dsRNA agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

### Claim at position 30

-121. (canceled)

### Claim 122 (depends on 1)

A cell containing the dsRNA agent of claim 1.

### Claim 123 (depends on 1)

A pharmaceutical composition for inhibiting expression of a metabolic disorder-associated target gene selected from the group consisting of inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), and inhibin subunit beta C (INHBC) comprising the dsRNA agent of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 33

-128. (canceled)

### Claim 129 (depends on 1)

A method of inhibiting expression of a metabolic disorder-associated target gene selected from the group consisting of inhibin subunit beta E (INHBE), activin A receptor type 1C (ACVR1C), perilipin-1 (PLIN1), phosphodiesterase 3B (PDE3B), and inhibin subunit beta C (INHBC) in a cell, the method comprising contacting the cell with the dsRNA agent of claim 1, thereby inhibiting expression of the metabolic disorder-associated target gene in the cell.

### Claim at position 35

-144. (canceled)

### Claim 145 (depends on 1)

A method of treating a subject having a metabolic disorder, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of claim 1, thereby treating the subject having the metabolic disorder.

### Claim at position 37

-169. (canceled)

### Claim 170 (depends on 1)

A kit, a vial, or a syringe comprising the dsRNA agent of claim 1.

### Claim at position 39

-173. (canceled)
